February 2015 in “American journal of medical and biological research” This study found that molecular differences in paracrine factors between balding and non-balding hair follicles may enhance understanding of androgen action in hair disorders and potentially inform better treatments.
March 2023 in “Research Square (Research Square)” In this study, researchers found that changes in immune cell infiltration and immune-related gene expression may contribute to the immune microenvironment changes in male androgenetic alopecia.
21 citations
,
September 2019 in “Journal of the American Academy of Dermatology” Ixekizumab effectively treats generalized pustular psoriasis.
5 citations
,
February 2022 in “Seminars in cell & developmental biology” This review discusses the complexities of hidradenitis suppurativa pathogenesis, highlighting issues with Notch signaling, immune dysregulation, and the role of keratinocytes and ECM, but reports no new clinical results.
1 citations
,
May 2017 in “InTech eBooks” This review addresses alopecia areata, emphasizing its autoimmune nature, unpredictable course, and lack of preventive or curative treatments, while noting standard and emerging therapies such as topical steroids and Janus kinase inhibitors.
January 2016 in “Springer eBooks” This review examines the clinical presentation and management strategies for alopecia areata, focusing on pediatric patients, and highlights the need for addressing its psychological impacts; it reports no new clinical findings.
October 2025 in “Australasian Journal of Dermatology” In this case report, a 31-year-old male with refractory sycosis barbae achieved complete remission after 4 months of treatment with bimekizumab, suggesting this dual inhibitor of interleukin-17A and IL-17F may be a promising therapy for this condition.
40 citations
,
July 2015 in “Kidney International” This study found that blocking interleukin-3 improved lupus nephritis symptoms in MRL/Ipr mice, suggesting IL-3 may play a role in the disease's progression.
25 citations
,
October 2019 in “JAAD Case Reports” This article discusses the role of interleukin-15 and Janus kinase inhibitors in alopecia areata based on a murine model and reports no new experimental results.
January 2022 in “Dermatology Review” This study found that patients with chronic kidney disease-associated pruritus had elevated serum levels of interleukin 31, suggesting a possible role of this cytokine in the condition.
24 citations
,
January 2016 in “Lasers in Medical Science” This study found that non-ablative fractional erbium glass laser treatment affected gene regulation in human skin models by downregulating MMP and interleukin expression, suggesting potential roles in dermal remodeling and anti-inflammatory effects.
2 citations
,
March 2025 in “International Journal of Dermatology” In this case report, the authors described a 46-year-old woman with severe atopic dermatitis and alopecia areata, who experienced significant improvements in both conditions after treatment with the interleukin-13 blocker tralokinumab, suggesting a potential therapeutic role for targeting type 2 cytokine IL-13 in such cases.
February 2026 in “Journal of Drugs in Dermatology” This case study reports on a 13-year-old male with alopecia totalis who experienced successful hair regrowth after being treated with dupilumab, an interleukin-4 and IL-13 antagonist, suggesting its potential utility in managing alopecia areata in pediatric patients with comorbid atopic dermatitis.
January 2026 in “International journal of research and scientific innovation” This paper reviews studies on stress-related biomarkers such as ghrelin, cortisol, and interleukin-6, highlighting their potential roles in stress and psychiatric illnesses, without providing new experimental data.
In a proof-of-concept study at Xiangya Hospital, the researchers observed that combining tofacitinib with low-dose interleukin-2 helped maintain remission in refractory alopecia areata patients, with three out of four maintaining complete remission for 11–20 months post-treatment and no adverse events reported.
May 2024 in “International journal of medicine and psychology.” In this study, researchers observed that transcranial electrical stimulation in COVID-19 patients with mild to moderate symptoms led to a trend of greater reduction in interleukin-10 levels and interleukin-10/lymphocyte ratio compared to standard treatment alone, suggesting potential impacts on immunosuppression mechanisms that warrant further investigation.
October 2015 in “Elsevier eBooks” Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.
23 citations
,
January 2016 in “Frontiers in immunology” This review discusses the potential of combining low-dose IL-2 with islet antigens to enhance antigen-specific Treg function in type 1 diabetes, but reports no new clinical results.
July 2019 in “Journal of the European Academy of Dermatology and Venereology” This study reported no measurable effect on libido or other sexual life parameters in finasteride users compared to non-users among male participants examined with the Arizona Sexual Experience scale.
1 citations
,
March 2019 in “Journal of Interdisciplinary Medicine” This case report details a middle-aged man with multiple sclerosis who developed difficult-to-evaluate skin reactions after daclizumab treatment, noting only slight improvement with additional therapies.
14 citations
,
January 2024 in “Burns & Trauma” In this study on diabetic wound healing in mice, Calvatia gigantea extract accelerated wound recovery, reduced inflammation, and improved the microbiome's diversity, particularly enhancing Escherichia–Shigella bacteria presence.
11 citations
,
October 2001 in “Dermatologic Clinics” In this study, subcutaneous recombinant human IL-12 showed a 43% partial response rate in early-stage mycosis fungoides patients refractory to previous treatments, with generally mild to moderate adverse events reported.
5 citations
,
April 2024 in “Journal of Ovarian Research” This study found that in mice with premature ovarian insufficiency, miR-21 enhances ovarian function recovery following umbilical cord-derived mesenchymal stem cell transplantation by influencing specific cellular signaling and immune pathways.
5 citations
,
July 2017 in “Molecular Medicine Reports” This study observed that ethanol extracts of Lygodium japonicum spores significantly reduced inflammatory responses in LPS-stimulated murine macrophages in vitro by negatively regulating p38 MAPK and NF-κB.
2 citations
,
May 2022 in “Tropical Journal of Pharmaceutical Research” In this meta-analysis, probiotic consumption in rheumatoid arthritis patients significantly improved disease activity scores and reduced certain inflammatory cytokines, but did not affect ACR20 response or other measured parameters compared to placebo.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
56 citations
,
November 2022 in “Biomolecules” This review explores the role of macrophage subsets in adult cutaneous wound healing and emphasizes their potential for therapeutic targeting, but reports no new experimental results.
23 citations
,
January 2024 in “Nature Immunology” This study, using multimodal profiling in mice, found that various tissues contain unique γδ T cell subsets adapted to their environment, revealing their functional diversity, lineage relationships, and similarities to CD8+ tissue-resident memory T cells.
22 citations
,
June 2018 in “Journal of Neuroinflammation” This study found that procyanidins effectively alleviate neuropathic pain in mice by significantly inhibiting MMP-9/2 activity.
21 citations
,
January 2024 in “Science Immunology” This study developed a technique to limit genetic recombination to regulatory T cells to investigate whether self-tolerance is maintained in non-lymphoid tissues, an area previously not well understood.